argenx SE (EBR:ARGX)
Belgium
· Delayed Price · Currency is EUR 469.80
-9.50 (-1.98%)
Jun 30, 2025, 5:36 PM CET
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
€1,529,306
Profits / Employee
€615,704
Market Cap
28.69B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UCB SA | 9,378 |
| Fagron NV | 3,828 |
| Ion Beam Applications | 2,287 |
| Nyxoah | 184 |
| Onward Medical | 103 |
| Hyloris Pharmaceuticals | 49 |
| Sequana Medical NV | 48 |
| European Medical Solutions | 122 |
argenx SE News
- 8 hours ago - Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin - Seeking Alpha
- 12 hours ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 12 hours ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 13 hours ago - argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo - Seeking Alpha
- 10 days ago - argenx gets EU nod for Vyvgart subcutaneous injection - Seeking Alpha
- 10 days ago - argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 14 days ago - $1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
- 20 days ago - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease - Benzinga